Catalyst Calendar

Fri, Oct 2, 2026

1 updates

9:00 AM

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria

Presentation / Abstract • Phase 2Phase 2 pooled analysis poster at ASN Kidney Week Fri, Oct 23, 2026, 10:00 AM MDTprokidney.com

Mon, Aug 10, 2026

1 updates

PROK

4:05 PM

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth

Enrollment • Phase 3Enrollment milestone Tue, Jun 30, 2026prokidney.com